CD137 (human):Fc (mouse) (rec.)
|Synonyms||Tumor Necrosis Factor Receptor Superfamily Member 9; TNFRSF9; 4-1BB; 4-1BB Ligand Receptor T Cell; Antigen 4-1BB Homolog; T Cell Antigen ILA; CD137 Antigen; CDw137; ILA; MGC2172|
|Source/Host||HEK 293 cells|
The extracellular domain of human CD137 [4-1BB] (aa 19-184) is fused to the N-terminus of the Fc region of mouse IgG2a.
Measured by its binding ability in a functional ELISA.
|Endotoxin Content||<5EU/mg protein (LAL test; Lonza).|
Reconstitute 100µg vial with 100 µl sterile water to a concentration of 1mg/ml.
Add 1X PBS to the desired protein concentration.
|Formulation||Lyophilized from 0.2μm-filtered solution in PBS.|
|Protein Negative Control|
|Other Product Data||
NCBI reference AAH06196.1: CD137 (human)
|Declaration||Manufactured by Chimerigen.|
|Shipping and Handling|
|Short Term Storage||+4°C|
|Long Term Storage||-20°C|
Avoid freeze/thaw cycles.
Centrifuge lyophilized vial before opening and reconstitution.
Stable for at least 1 year after receipt when stored at -20°C.
Working aliquots are stable for up to 3 months when stored at -20°C.
|Product Specification Sheet|
Human CD137 (4-1BB) is a costimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. The glycoprotein 4-1BB is expressed mainly on activated CD4+ and CD8+ T cells and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor receptor-associated factors (TRAF), the adaptor protein and mediates downstream signaling events including the activation of NF-κB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T cell activation and growth as well as monocyte proliferation and B cell survival, and plays a important role in the amplification of T cell-mediated immune responses. In contrast, it can also enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, the 4-1BB/4-1BBL costimulatory pathway has been shown to augment secondary CTL responses to several viruses and increase antitumor immunity. 4-1BB is therefore a promising candidate for immunotherapy of human cancer.